Updated:
LYFE Capital Management
LYFE Capital Management is a Shanghai-based private equity firm founded by Jian Wang in 2010 deploying capital in US and Asian healthcare companies.
LYFE Capital Management
LYFE Capital Management was founded in 2010 by Jian Wang, a veteran private equity investor with deep ties in both China and the United States. The firm initially raised capital from institutional investors and family offices in Greater China, later expanding its limited-partner base to include global allocators seeking healthcare exposure. The firm deploys capital across growth equity and buyout transactions in the health and life sciences sectors, targeting companies in biotechnology, medical devices, diagnostics, and healthcare services. Its portfolio includes investments in US-based biotech firms such as those developing novel therapeutics and diagnostics, alongside Asian healthcare service providers. Geographically, LYFE Capital operates across China and the United States. LYFE Capital has deployed over $1 billion since inception (public record). The team includes Managing Director Ben Cherry, who oversees US investments. In 2023, the firm closed a new fund focused on cross-border healthcare deals, raising capital from existing and new LPs (per public record, 2023). LYFE Capital's structural differentiator lies in its dual-geography mandate: it is one of the few private equity firms based in China that systematically invests in both US and Asian healthcare companies, leveraging its on-the-ground presence in Shanghai to source proprietary deal flow in China while partnering with US life sciences companies for growth capital.
General information
Firm type
Asset Manager
Year founded
2010
AUM
$1B - $5B (Altss estimate)
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Principals
Ben Cherry
Managing Director
Jian Wang
Founder & Managing Partner
Sector focus
Frequently asked questions
What is LYFE Capital Management's primary investment focus?
LYFE Capital Management focuses exclusively on health and life sciences sectors, including biotechnology, medical devices, diagnostics, and healthcare services. The firm invests in both growth equity and buyout transactions.
How does LYFE Capital source proprietary deal flow?
LYFE Capital leverages its Shanghai headquarters and US connections to source cross-border healthcare deals. The firm has deep relationships with Chinese hospital networks, biotech entrepreneurs, and US life sciences advisory firms, allowing it to identify investment opportunities in both markets.
Does LYFE Capital invest in both China and the United States?
Yes, LYFE Capital is one of the few private equity firms headquartered in China that systematically invests in both US and Asian healthcare companies. It has a dedicated US investment team led by Managing Director Ben Cherry (per public record).
What is the typical investment size and stage for LYFE Capital?
LYFE Capital typically targets growth equity and buyout investments ranging from $10 million to $100 million per transaction. The firm focuses on established companies with proven technology or market traction rather than early-stage startups.
How is LYFE Capital related to other Asian healthcare investors?
LYFE Capital operates independently as a Shanghai-based private equity firm. It is not affiliated with any single Chinese corporation or family office but has relationships with institutional investors and family offices in Greater China.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: